Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

American Journal of Cardiology

Volumn 102, Issue 1, 2008, Pages 12-18

  Gómez Hernández, Almudena ^a   Sánchez Galán, Eva ^a   Ortego, Mónica ^a   Martín Ventura, José Luis ^a   Blanco Colio, Luis Miguel ^a   Tarín Vicente, Nieves ^b   Jiménez Nacher, José Julio ^c   López Bescos, Lorenzo ^c,d   Egido, Jesús ^a   Tuñón, José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4; PROSTAGLANDIN E2; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT DURATION; ZYMOGRAPHY;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; DINOPROSTONE; ELECTROCARDIOGRAPHY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOTRIENE B4; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; PYRROLES; TREATMENT OUTCOME;

EID: 51749108882     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.090     Document Type: Article

References (27)

1. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic L., Szarek M., Welch K.M., Zivin J.A., and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
2. Tuñón J., Martín-Ventura J.L., Blanco-Colio L.M., and Egido J. Mechanisms of action of statins in stroke. Expert Opin Ther Targets 11 (2007) 273-278
3. Martín-Ventura J.L., Blanco-Colio L.M., Muñoz-García B., Gómez-Hernández A., Arribas A., Ortega L., Tuñón J., and Egido J. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 35 (2004) 458-463
4. Gómez-Hernández A., Martín-Ventura J.L., Sánchez-Galán E., Vidal C., Ortego M., Blanco-Colio L.M., Ortega L., Tuñón J., and Egido J. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis 187 (2006) 139-149
5. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 (2002) 5-12
6. de Winther M.P., Kanters E., Kraal G., and Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25 (2005) 904-914
7. Wilson S.H., Best P.J., Edwards W.D., Holmes Jr. D.R., Carlson P.J., Celermajer D.S., and Lerman A. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 160 (2002) 147-153
8. Ritchie M.E. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 98 (1998) 1707-1713
9. Liuzzo G., Santamaria M., Biasucci L.M., Narducci M., Colafrancesco V., Porto A., Brugaletta S., Pinnelli M., Rizzello V., Maseri A., and Crea F. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol 49 (2007) 185-194
10. Mulvihill N.T., Foley J.B., Murphy R., Crean P., and Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 36 (2000) 1210-1216
11. Barderas M.G., Tuñón J., Dardé V.M., De la Cuesta F., Durán M.C., Jiménez-Nácher J.J., Tarín N., López-Bescós L., Egido J., and Vivanco F. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res 6 (2007) 876-886
12. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoids receptors: structures, properties and functions. Physiol Rev 79 (1999) 1193-1226
13. Cipollone F., Prontera C., Pini B., Marini M., Fazia M., De Cesare D., Iezzi A., Ucchino S., Boccoli G., Saba V., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basic of prostaglandin E(2)-dependent plaque instability. Circulation 104 (2001) 921-927
14. Beloqui O., Paramo J.A., Orbe J., Benito A., Colina I., Monasterio A., and Díez J. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J 26 (2005) 153-158
15. Bäck M., Bu D.X., Bränström R., Sheikine Y., Yan Z.Q., and Hansson G.K. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 102 (2005) 17501-17506
16. Huang L., Zhao A., Wong F., Ayala J.M., Struthers M., Ujjainwalla F., Wright S.D., Springer M.S., Evans J., and Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24 (2004) 1783-1788
17. Cipollone F., Mezzetti A., Fazia M.L., Cuccurullo C., Iezzi A., Ucchino S., Spigonardo F., Bucci M., Cuccurullo F., Prescott S.M., and Stafforini D.M. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 25 (2005) 1665-1670
18. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., and Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
19. Hakonarson H., Thorvaldsson S., Helgadottir A., Gudbjartsson D., Zink F., Andresdottir M., Manolescu A., Arnar D.O., Andersen K., Sigurdsson A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. JAMA 293 (2005) 2245-2256
20. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., Samani N.J., Gudmundsson G., Grant S.F., Thorgeirsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
21. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
22. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
23. Chen F., Eriksson P., Hansson G.K., Herzfeld I., Klein M., Hansson L.O., and Valen G. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 15 (2005) 57-65
24. Brown D.L., Hibbs M.S., Kearney M., Loushin C., and Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91 (1995) 2125-2131
25. Cipollone F., Fazia M., Iezzi A., Zucchelli M., Pini B., De Cesare D., Ucchino S., Spigonardo F., Bajocchi G., Bei R., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107 (2003) 1479-1485
26. Martín-Ventura J.L., Blanco-Colio L.M., Gómez-Hernández A., Muñoz-García B., Vega M., Serrano J., Ortega L., Hernández G., Tuñón J., and Egido J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 (2005) 1796-1800
27. Xu Z., Zhao S., Zhou H., Ye H., and Li J. Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem 50 (2004) 750-753